These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16298583)

  • 61. The long-term effects of immune suppression on liver transplant recipients with recurrent hepatitis C viral infection.
    Neff GW; delaGarza J; Shire N; Nishida S; O'Brien CB; Safdar K; Madariaga J; Schiff E; Ruiz P
    Transplant Proc; 2004 Dec; 36(10):3065-7. PubMed ID: 15686695
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Intentional conversion from tacrolimus to cyclosporine for HCV-positive patients on preemptive interferon therapy after living donor liver transplantation.
    Eguchi S; Takatsuki M; Soyama A; Hidaka M; Tokai H; Hamasaki K; Miyazaki K; Tajima Y; Ichikawa T; Kanematsu T
    Ann Transplant; 2007; 12(4):11-5. PubMed ID: 18344932
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pegylated interferon treatment of acute pericarditis associated with acute hepatitis C.
    Kocaman O; Aygün C; Konduk T; Celebi A; Sentürk O; Hülagü S
    Turk J Gastroenterol; 2007 Dec; 18(4):268-71. PubMed ID: 18080927
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment of hepatitis C virus reinfection after liver transplantation.
    Encke J; Kraus T; Mehrabi A; Stremmel W; Sauer P
    Transplantation; 2005 Sep; 80(1 Suppl):S125-7. PubMed ID: 16286889
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Successful liver transplantation and treatment of recurrent hepatitis C using pegylated alpha-interferon in a patient with Churg-Strauss disease.
    Falkensammer J; Bonatti H; Dickson RC; Norman K; Nguyen J; Hinder R; Aranda-Michel J
    Transpl Int; 2007 Feb; 20(2):190-4. PubMed ID: 17239028
    [TBL] [Abstract][Full Text] [Related]  

  • 66. rs8099917 and viral genotyping as indications for living donor liver transplantation for hepatitis C: a case report.
    Yoshida Y; Ikegami T; Yoshizumi T; Toshima T; Yamashita YI; Yoshiya S; Shirabe K; Maehara Y
    Transplant Proc; 2014 Sep; 46(7):2426-9. PubMed ID: 25150603
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b.
    Haagsma EB; Riezebos-Brilman A; van den Berg AP; Porte RJ; Niesters HG
    Liver Transpl; 2010 Apr; 16(4):474-7. PubMed ID: 20373458
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pre-emptive treatment of recurrent hepatitis C infection.
    Charlton M
    Liver Transpl; 2002 Oct; 8(10 Suppl 1):S50-4. PubMed ID: 12362299
    [No Abstract]   [Full Text] [Related]  

  • 69. Cholestatic hepatitis due to hepatitis C virus after a living donor liver transplantation.
    Kaneko J; Sugawara Y; Akamatsu N; Kokudo N; Makuuchi M
    Hepatogastroenterology; 2004; 51(55):243-4. PubMed ID: 15011874
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A case of myelodysplastic syndrome in a liver transplant patient.
    Potru R; Ahn J; Fung H; Cohen SM
    Transplant Proc; 2009 Nov; 41(9):3947-8. PubMed ID: 19917420
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Induced interstitial pneumonitis: role of pegylated interferon alpha 2b].
    Rocca P; Dumortier J; Tanière P; Duperret S; Vial T; Cottin V; Delafosse B; Scoazec JY; Boillot O
    Gastroenterol Clin Biol; 2002 Apr; 26(4):405-8. PubMed ID: 12070414
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Preemptive therapy for hepatitis C virus after living-donor liver transplantation.
    Sugawara Y; Makuuchi M; Matsui Y; Kishi Y; Akamatsu N; Kaneko J; Kokudo N
    Transplantation; 2004 Nov; 78(9):1308-11. PubMed ID: 15548968
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Hepatitis C and alcohol, which is the limit?].
    Lampo N; Malinverni R
    Rev Med Suisse Romande; 2003 Apr; 123(4):241-3. PubMed ID: 15088556
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Liver transplantation and hepatitis C virus: systematic review of antiviral therapy.
    Triantos C; Samonakis D; Stigliano R; Thalheimer U; Patch D; Burroughs A
    Transplantation; 2005 Feb; 79(3):261-8. PubMed ID: 15699754
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Liver transplantation from an identical twin without immunosuppression, with early recurrence of hepatitis C.
    Yoshizawa A; Takada Y; Fujimoto Y; Koshiba T; Haga H; Nabeshima S; Uemoto S
    Am J Transplant; 2006 Nov; 6(11):2812-6. PubMed ID: 16939511
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antiviral Therapy for Hepatitis C.
    Lipman MM; Cotler SJ
    Curr Treat Options Gastroenterol; 2003 Dec; 6(6):445-453. PubMed ID: 14585233
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Early use of interferon alfa-2a can stop HCV infection.
    Traynor K
    Am J Health Syst Pharm; 2001 Nov; 58(22):2119-20. PubMed ID: 11760908
    [No Abstract]   [Full Text] [Related]  

  • 78. [A case of anti-HCV treatment in cirrhosis patient with vitiligo].
    Kang HY; Wang JB; Zhao ZL; Wang Y; Liu YH
    Zhonghua Gan Zang Bing Za Zhi; 2012 Mar; 20(3):236. PubMed ID: 22629582
    [No Abstract]   [Full Text] [Related]  

  • 79. Recurrent hepatitis C in transplanted patients: more questions than answers.
    Bahr MJ; Manns MP
    Dig Liver Dis; 2003 Jan; 35(1):2-6. PubMed ID: 12725599
    [No Abstract]   [Full Text] [Related]  

  • 80. Hepatitis C-related cirrhosis with sustained prevention of hepatocellular carcinoma recurrence by long-term administration of super-low-dose peginterferon-alpha 2b.
    Mamori S; Mamori H
    Case Rep Gastroenterol; 2011 Jan; 5(1):56-62. PubMed ID: 21537363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.